Using clinically relevant animal models, we have recently demonstrated that the anticonvulsant primidone (Liskantin<sup>®</sup>), approved by the FDA for the treatment of various forms of epilepsy, can effectively block RIPK1 enzymatic activity, which mediates cell death, and consequently prevent RIPK1 cytotoxicity and associated inflammatory responses. Here, RIPK1 is linked to epilepsy.